High MET expression is an adverse prognostic factor in patients with triple-negative breast cancer

British Journal of Cancer

Volumn 108, Issue 5, 2013, Pages 1100-1105

  Zagouri, F ^a   Bago Horvath, Z ^a   Rossler F ^a   Brandstetter, A ^a   Bartsch, R ^a   Papadimitriou, C A ^b   Dimitrakakis, C ^b   Tsigginou, A ^b   Papaspyrou, I ^b   Giannos, A ^b   Dimopoulos, M A ^b   Filipits, M ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF ATHENS   (Greece)

Author keywords

biomarkers; MET; prognosis; triple negative breast cancer

Indexed keywords

SCATTER FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SIZE; CANCER SURVIVAL; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENCE FREE SURVIVAL; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MIDDLE AGED; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RECURRENCE; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84875418041     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.31     Document Type: Article

References (29)

1. Camp RL, Rimm EB, Rimm DL (1999) Met expression is associated with pooroutcome in patients with axillary lymph node negative breast carcinoma.Cancer 86 (11) : 2259-2265.
2. Dent R, Trudeau M, Pritchard KI, Hanna WM, Kahn HK, Sawka CA, LickleyLA, Rawlinson E, Sun P, Narod SA (2007) Triple-negative breast cancer:clinical features and patterns of recurrence. Clin Cancer Res 13 (15 Pt 1) :4429-4434.
3. Di Renzo MF, Olivero M, Giacomini A, Porte H, Chastre E, Mirossay L, Nordlinger B, Bretti S, Bottardi S, Giordano S et al. (1995) Overexpressionand amplification of the met/HGF receptor gene during the progression ofcolorectal cancer. Clin Cancer Res 1 (2) : 147-154.
4. Di Renzo MF, Olivero M, Martone T, Maffe A, Maggiora P, Stefani AD, Valente G, Giordano S, Cortesina G, Comoglio PM (2000) Somaticmutations of the MET oncogene are selected during metastatic spread ofhuman HNSC carcinomas. Oncogene 19 (12) : 1547-1555.
5. Dziadziuszko R, Wynes MW, Singh S, Asuncion BR, Ranger-Moore J, KonopaK, Rzyman W, Szostakiewicz B, Jassem J, Hirsch FR (2012) Correlationbetween MET gene copy number by silver in situ hybridization andprotein expression by immunohistochemistry in non-small cell lungcancer. J Thorac Oncol 7 (2) : 340-347.
6. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G (2012) TargetingMET in cancer: rationale and progress. Nat Rev Cancer 12 (2) : 89-103.
7. Ghoussoub RA, Dillon DA, D'Aquila T, Rimm EB, Fearon ER, Rimm DL (1998) Expression of c-met is a strong independent prognostic factor inbreast carcinoma. Cancer 82 (8) : 1513-1520.
8. Goldman JW, Laux I, Chai F, Savage RE, Ferrari D, Garmey EG, Just RG, Rosen LS (2012) Phase 1 dose-escalation trial evaluating the combinationof the selective MET (mesenchymal-epithelial transition factor) inhibitortivantinib (ARQ 197) plus erlotinib. Cancer 118 (23) : 5903-5911.
9. Gonzalez-Angulo AM, Chen H, Karuturi MS, Chavez-Macgregor M, Tsavachidis S, Meric-Bernstam F, Do KA, Hortobagyi GN, Thompson PA, Mills GB, Bondy ML, Blumenschein Jr GR (2012) Frequency ofmesenchymal-epithelial transition factor gene (MET) and the catalyticsubunit of phosphoinositide-3-kinase (PIK3CA) copy number elevationand correlation with outcome in patients with early stage breast cancer.Cancer 119 (1) : 7-15.
10. Graveel C, Su Y, Koeman J, Wang LM, Tessarollo L, Fiscella M, Birchmeier C, Swiatek P, Bronson R, Vande Woude G (2004) Activating Met mutationsproduce unique tumor profiles in mice with selective duplication of themutant allele. Proc Natl Acad Sci USA 101 (49) : 17198-17203.
11. Haffty BG, Yang Q, Reiss M, Kearney T, Higgins SA, Weidhaas J, Harris L, Hait W, Toppmeyer D (2006) Locoregional relapse and distant metastasisin conservatively managed triple negative early-stage breast cancer. J ClinOncol 24 (36) : 5652-5657.
12. Houldsworth J, Cordon-Cardo C, Ladanyi M, Kelsen DP, Chaganti RS (1990) Gene amplification in gastric and esophageal adenocarcinomas. CancerRes 50 (19) : 6417-6422.
13. Lengyel E, Prechtel D, Resau JH, Gauger K, Welk A, Lindemann K, Salanti G, Richter T, Knudsen B, Vande Woude GF, Harbeck N (2005) C-Metoverexpression in node-positive breast cancer identifies patients with poorclinical outcome independent of Her2/neu. Int J Cancer 113 (4) : 678-682.
14. Moss RA, Bothos JG, Filvaroff E, Merchant M, Eppler S, Yu W, Harris K, ScottP, Mehnert JM, Patel PH (2010a) Phase Ib dose-escalation study ofMetMAb, a monovalent antagonist antibody to the receptor MET, incombination with bevacizumab in patients with locally advanced ormetastatic solid tumors. J Clin Oncol 28 (suppl) : abstr e13050.
15. Moss RA, Patel P, Bothos J, Peterson AC, Eppler S, Yu W (2010b) Completeresults from phase I dose escalation study of MetMAb, a monovalentantagonist antibody to the receptor Met, dosed as single agent and incombination with bevacizumab in patients with advanced solidmalignancies. Ann Oncol 21, viii165 (Suppl. 168) : abstract 504P.
16. Nakopoulou L, Gakiopoulou H, Keramopoulos A, Giannopoulou I, Athanassiadou P, Mavrommatis J, Davaris PS (2000) c-Met tyrosinekinase receptor expression is associated with abnormal beta-cateninexpression and favourable prognostic factors in invasive breast carcinoma.Histopathology 36 (4) : 313-325.
17. Oliner KS, Tang R, Anderson A, Lan Y, Iveson T, Donehower RC, Jiang Y, Dubey S, Loh E (2012) Evaluation of MET pathway biomarkers in a phaseII study of rilotumumab (R, AMG 102) or placebo (P) in combinationwith epirubicin, cisplatin, and capecitabine (ECX) in patients (pts) withlocally advanced or metastatic gastric (G) or esophagogastric junction (EGJ) cancer. J Clin Oncol 30 (suppl) : abstr 4005.
18. Perisanidis C, Wrba F, Brandstetter A, Kornek G, Mitchell D, Seemann R, Selzer E, Ewers R, Filipits M (2012) Impact of epidermal growth factorreceptor, mesenchymal-epithelial transition factor, and insulin-like growthfactor receptor 1 expression on survival of patients with oral andoropharyngeal cancer. Br J Oral Maxillofac Surg; e-pub ahead of print11 August 2012; doi:10.1016/j.bjoms. 2012.06.009.
19. Ponzo MG, Lesurf R, Petkiewicz S, O'Malley FP, Pinnaduwage D, Andrulis IL, Bull SB, Chughtai N, Zuo D, Souleimanova M, Germain D, Omeroglu A, Cardiff RD, Hallett M, Park M (2009) Met induces mammary tumors withdiverse histologies and is associated with poor outcome and human basalbreast cancer. Proc Natl Acad Sci USA 106 (31) : 12903-12908.
20. Rege-Cambrin G, Scaravaglio P, Carozzi F, Giordano S, Ponzetto C, ComoglioPM, Saglio G (1992) Karyotypic analysis of gastric carcinoma cell linescarrying an amplified c-met oncogene. Cancer Genet Cytogenet 64 (2) :170-173.
21. Rosen LS, Senzer N, Mekhail T, Ganapathi R, Chai F, Savage RE, Waghorne C, Abbadessa G, Schwartz B, Dreicer R (2011) A phase I dose-escalationstudy of tivantinib (ARQ 197) in adult patients with metastatic solidtumors. Clin Cancer Res 17 (24) : 7754-7764.
22. Scagliotti GV, Novello S, Schiller JH, Hirsh V, Sequist LV, Soria JC, von PawelJ, Schwartz B, Von Roemeling R, Sandler AB (2012) Rationale and designof MARQUEE: a phase III, randomized, double-blind study of tivantinibplus erlotinib versus placebo plus erlotinib in previously treated patientswith locally advanced or metastatic, nonsquamous, non-small-cell lungcancer. Clin Lung Cancer 13 (5) : 391-395.
23. Sequist LV, von Pawel J, Garmey EG, AkerleyWL, Brugger W, Ferrari D, ChenY, Costa DB, Gerber DE, Orlov S, Ramlau R, Arthur S, Gorbachevsky I, Schwartz B, Schiller JH (2011) Randomized phase II study of erlotinib plustivantinib versus erlotinib plus placebo in previously treated non-small-celllung cancer. J Clin Oncol 29 (24) : 3307-3315.
24. Sierra JR, Tsao MS (2011) c-MET as a potential therapeutic target andbiomarker in cancer. Ther Adv Med Oncol 3 (1 Suppl) : S21-S35.
25. Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH, BlumenscheinGR, Krzakowski MJ, Robinet G, Clement-Duchene C, Barlesi F, GovindanR, Patel T, Orlov SV, Wertheim MS, Zha J, Pandita A, Yu W, Yauch RL, Patel PH, Peterson AC (2011) Final efficacy results from OAM4558g, arandomized phase II study evaluating MetMAb or placebo in combinationwith erlotinib in advanced NSCLC. J Clin Oncol 29 (suppl) : abstr 7505.
26. Tischkowitz M, Brunet JS, Begin LR, Huntsman DG, Cheang MC, Akslen LA, Nielsen TO, Foulkes WD (2007) Use of immunohistochemical markerscan refine prognosis in triple negative breast cancer. BMC Cancer 7: 134.
27. Tolgay Ocal I, Dolled-Filhart M, D'Aquila TG, Camp RL, Rimm DL (2003) Tissue microarray-based studies of patients with lymph node negativebreast carcinoma show that met expression is associated with worseoutcome but is not correlated with epidermal growth factor familyreceptors. Cancer 97 (8) : 1841-1848.
28. Wullich B, Sattler HP, Fischer U, Meese E (1994) Two independentamplification events on chromosome 7 in glioma: amplification of theepidermal growth factor receptor gene and amplification of the oncogeneMET. Anticancer Res 14 (2A) : 577-579.
29. Yap TA, Olmos D, Brunetto AT, Tunariu N, Barriuso J, Riisnaes R, Pope L, Clark J, Futreal A, Germuska M, Collins D, deSouza NM, Leach MO, Savage RE, Waghorne C, Chai F, Garmey E, Schwartz B, Kaye SB, de BonoJS (2011) Phase I trial of a selective c-MET inhibitor ARQ 197incorporating proof of mechanism pharmacodynamic studies. J Clin Oncol29 (10) : 1271-1279.